ArticleMedComm2025

Camrelizumab, an Anti-PD-1 Monoclonal Antibody, Plus Carboplatin and Nab-Paclitaxel as First-Line Setting for Extensive-Stage Small-Cell Lung Cancer: A Phase 2 Trial and Biomarker Analysis.

Jia Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.